Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
This was the stock's third consecutive day of gains.
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
On February 18, 2025, the First Circuit Court of Appeals issued its decision in U.S. v. Regeneron Pharmaceuticals, ruling ...
European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...
Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...
In the current market session, Regeneron Pharmaceuticals Inc. REGN share price is at $695.58, after a 0.06% decrease. Over the past month, the stock spiked by 2.93%, but over the past year, it ...
Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation ...
Regeneron Pharmaceuticals Inc. convinced the First Circuit to impose a higher causation standard in the government’s False Claims Act case alleging a drug kickback scheme, according to a Tuesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results